Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

tertatolol

Known as: 1-((3,4-Dihydro-2H-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)-2-propanol, 2-propanol, 1-((3,40dihydro-2H-1-benzothiopyran-8-yl)oxy)-3-((1,1-dimethylethyl)amino)-, Racemic Teraterol 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
A new rapid and sensitive high-performance liquid chromatography (HPLC) method has been developed for the simultaneous… Expand
Highly Cited
2004
Highly Cited
2004
In humans, lipid mobilization is considered to depend mainly on sympathetic nervous system activation and catecholamine action. A… Expand
Highly Cited
2000
Highly Cited
2000
A novel strategy for improving the treatment of depressive illness is augmentation of antidepressants with a 5-HT11A autoreceptor… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
Highly Cited
1998
Highly Cited
1998
Electrophysiological techniques were used to study the effects of paroxetine, sertraline, and fluvoxamine on the basal activity… Expand
Highly Cited
1994
Highly Cited
1994
The behavioural response of rats in the high light unfamiliar condition of the social interaction test of anxiety was observed… Expand
1993
1993
The interaction of tertatolol (d,l-hydroxy-2'-t-butylamino-3'propyloxy-8-thiochromane HCl) with 5-hydroxytryptamine (serotonin; 5… Expand
Review
1991
Review
1991
Atenolol is a selective beta 1-adrenoceptor antagonist with a duration of activity of at least 24 hours. The scope of therapeutic… Expand
  • figure 1
  • figure 2
  • table I
  • figure 3
  • figure 4
1989
1989
In 15 previously untreated hypertensive subjects with left ventricular (LV) hypertrophy who responded favorably (supine blood… Expand
1988
1988
We have previously reported that a potent new beta-blocker, tertatolol, when given at therapeutic doses to healthy volunteers… Expand
1986
1986
Tertatolol is a potent new β‐blocker with no intrinsic sympathomimetic activity or β1/β2‐receptor subtype selectivity. When given… Expand